PDF(Pubmed)
Abstract：
UNASSIGNED: Cartilaginous tumors of the larynx are rare, representing less than 1% of all laryngeal tumors. Chondromas are benign mesenchymal tumors characterized by a slow-paced growth, primarily originated in the cricoid cartilage, followed by the thyroid, arytenoid, and epiglottic cartilages. This scoping review aims to understand the extent of evidence on the epidemiology, clinical characteristics, morbidity, and recurrence of the laryngeal chondroma (LC).
UNASSIGNED: MEDLINE (Ovid), Embase (Elsevier), Web of Science (Clarivate), Cochrane Central Register of Controlled Trials and Systematic Reviews, Lilacs, Scopus, and Google Scholar databases.
UNASSIGNED: The scoping review was conducted from 1816 to 2023, for observational studies describing LC. Titles and abstracts were screened for relevance, followed by an evaluation of the full text for eligibility. The data were collected from the qualifying articles, and a narrative summary of the outcomes was prepared.
UNASSIGNED: One hundred and nineteen studies met the inclusion criteria. Ninety-four case reports, 22 case series, and 3 cohorts. Two hundred and four participants with a diagnosis of LC were described. Male:female ratio was 2.8:1. The most common localization was the cricoid (113; 47.08%), followed by the thyroid (45; 18.75%), and the arytenoid cartilage (27; 11.25%). Dyspnea (78.85%) and hoarseness (74.28%) were the most reported symptoms. The recurrence rate was 11.25%, and complications were uncommon following the resection.
UNASSIGNED: This scoping review found a low-frequency rate over all the cartilaginous laryngeal tumors. Most patients were treated with resection, with a low rate of malignancy conversion. This population has low attributable mortality, morbidity, and recurrence according to the current literature.
UNASSIGNED: MEDLINE (Ovid), Embase (Elsevier), Web of Science (Clarivate), Cochrane Central Register of Controlled Trials and Systematic Reviews, Lilacs, Scopus, and Google Scholar databases.
UNASSIGNED: The scoping review was conducted from 1816 to 2023, for observational studies describing LC. Titles and abstracts were screened for relevance, followed by an evaluation of the full text for eligibility. The data were collected from the qualifying articles, and a narrative summary of the outcomes was prepared.
UNASSIGNED: One hundred and nineteen studies met the inclusion criteria. Ninety-four case reports, 22 case series, and 3 cohorts. Two hundred and four participants with a diagnosis of LC were described. Male:female ratio was 2.8:1. The most common localization was the cricoid (113; 47.08%), followed by the thyroid (45; 18.75%), and the arytenoid cartilage (27; 11.25%). Dyspnea (78.85%) and hoarseness (74.28%) were the most reported symptoms. The recurrence rate was 11.25%, and complications were uncommon following the resection.
UNASSIGNED: This scoping review found a low-frequency rate over all the cartilaginous laryngeal tumors. Most patients were treated with resection, with a low rate of malignancy conversion. This population has low attributable mortality, morbidity, and recurrence according to the current literature.
摘要：
■喉软骨瘤很少见，占所有喉部肿瘤的不到1%。软骨瘤是良性间质瘤，其特征是生长缓慢，主要起源于环状软骨，其次是甲状腺，Arytenoid,和会厌软骨.本范围审查旨在了解流行病学证据的范围，临床特征,发病率，喉软骨瘤（LC）复发。
■MEDLINE(Ovid),Embase(Elsevier),WebofScience(Clarivate),Cochrane中央对照试验和系统审查登记册，丁香花,Scopus,和谷歌学者数据库。
■范围审查于1816年至2023年进行，用于描述LC的观察性研究。标题和摘要进行了相关性筛选，然后对全文进行资格评估。数据是从合格的文章中收集的，并对结果进行了叙述性总结。
■一百一十九项研究符合纳入标准。94例病例报告,22个案例系列，和3个队列。描述了两百四名诊断为LC的参与者。男性：女性比例为2.8：1。最常见的定位是环状软骨(113;47.08%),其次是甲状腺（45;18.75％），andarytenoid软骨（27；11.25％）。呼吸困难（78.85％）和声音嘶哑（74.28％）是最多的报告症状。复发率为11.25%,切除后并发症并不常见。
■这项范围审查发现所有软骨喉肿瘤的低频率率。大多数患者接受了切除治疗，恶性肿瘤转化率低。该人群的归因死亡率较低，发病率，和复发根据目前的文献。
■MEDLINE(Ovid),Embase(Elsevier),WebofScience(Clarivate),Cochrane中央对照试验和系统审查登记册，丁香花,Scopus,和谷歌学者数据库。
■范围审查于1816年至2023年进行，用于描述LC的观察性研究。标题和摘要进行了相关性筛选，然后对全文进行资格评估。数据是从合格的文章中收集的，并对结果进行了叙述性总结。
■一百一十九项研究符合纳入标准。94例病例报告,22个案例系列，和3个队列。描述了两百四名诊断为LC的参与者。男性：女性比例为2.8：1。最常见的定位是环状软骨(113;47.08%),其次是甲状腺（45;18.75％），andarytenoid软骨（27；11.25％）。呼吸困难（78.85％）和声音嘶哑（74.28％）是最多的报告症状。复发率为11.25%,切除后并发症并不常见。
■这项范围审查发现所有软骨喉肿瘤的低频率率。大多数患者接受了切除治疗，恶性肿瘤转化率低。该人群的归因死亡率较低，发病率，和复发根据目前的文献。
